Published in
Springer, Cancer Immunology, Immunotherapy, 3(70), p. 743-753, 2020
DOI: 10.1007/s00262-020-02720-7
Links
Tools
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)
Journal article published in 2020 by
J. Chandra 
,
W. P. Woo,
N. Finlayson,
H. Y. Liu ,
M. McGrath,
R. Ladwa ,
M. Brauer,
Y. Xu,
S. Hanson ,
B. Panizza ,
I. H. Frazer ,
Sandro V. Porceddu
,
W. P. Woo,
N. Finlayson,
H. Y. Liu ,
M. McGrath,
R. Ladwa ,
M. Brauer,
Y. Xu,
S. Hanson ,
B. Panizza ,
I. H. Frazer ,
Sandro V. Porceddu
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 